Kühne Escolà Jordi, Nagel Simon, Panitz Verena, Reiff Tilman, Gutschalk Alexander, Gumbinger Christoph, Purrucker Jan Christoph
Department of Neurology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
J Clin Med. 2021 May 2;10(9):1956. doi: 10.3390/jcm10091956.
Managing acute ischemic stroke (AIS) in patients receiving treatment with vitamin K antagonists (VKA) or non-VKA oral anticoagulants (NOACs) is difficult and the challenge this poses for stroke telemedicine remains unexplored.
We analyzed data from a random sample ( = 1500) of all teleneurological consultations conducted between July 2015 and December 2017. Management of patients suffering AIS with and without prior oral anticoagulation treatment was characterized, including potential vs. actual treatment with intravenous thrombolysis (IVT) and reasons for withholding it.
= 359 patients had suffered an AIS, of whom 63 (17.5%) were under treatment with oral anticoagulants (VKA, = 24; NOAC, = 39). Administration of IVT was more common in patients who had not received prior oral anticoagulation treatment (20.3% vs. 3.2%, < 0.001). NOAC intake was the primary reason for withholding IVT in 37% of orally anticoagulated patients who were found potentially eligible for IVT. Furthermore, patients under oral anticoagulation tended to be transported to the comprehensive stroke center more often (23.8% vs. 13.9%, = 0.056).
AIS in patients on oral anticoagulation treatment is a frequent reason for telestroke consultation, and NOAC intake constitutes an important barrier to administering IVT.
对于正在接受维生素K拮抗剂(VKA)或非VKA口服抗凝剂(NOAC)治疗的患者,急性缺血性卒中(AIS)的管理存在困难,而这给卒中远程医疗带来的挑战仍未得到探索。
我们分析了2015年7月至2017年12月期间所有远程神经科会诊的随机样本(n = 1500)的数据。对有或没有先前口服抗凝治疗的AIS患者的管理进行了描述,包括静脉溶栓(IVT)的潜在治疗与实际治疗情况以及不进行IVT的原因。
359例患者发生了AIS,其中63例(17.5%)正在接受口服抗凝剂治疗(VKA,n = 24;NOAC,n = 39)。IVT在未接受先前口服抗凝治疗的患者中更常见(20.3%对3.2%,P < 0.001)。在37%被发现可能符合IVT条件的口服抗凝患者中,服用NOAC是不进行IVT的主要原因。此外,接受口服抗凝治疗的患者更常被转运到综合卒中中心(23.8%对13.9%,P = 0.056)。
口服抗凝治疗的患者发生AIS是远程卒中会诊的常见原因,服用NOAC是进行IVT的重要障碍。